This report will focuse on clinical difficulties, technical transformation paths, and international cooperation possibilities of proton therapy. The construction history, development scale, core technologies, and clinical achievements of China’s proton therapy centers, especially the progress of proton therapy in Shandong Cancer Hospital will be introduced systematically. In addition, this...
The NHa C400 [1] is an isochronous cyclotron for cancer therapy which can deliver high intensity of alphas to carbons at 400 MeV/amu and protons at 260 MeV. It is the first cyclotron-based clinical carbon therapy solution worldwide characterized by K=1600, this is the strongest compact cyclotron. Most of the part of the cyclotron has been constructed and assembled as well as subsystems such:...
Heavy ion beam therapy has become an important modality in cancer treatment due to its characteristic Bragg peak and high relative biological effectiveness. Currently, there are 18 heavy ion therapy centers in operation worldwide, with 5 located in mainland China. This paper focuses on the current status of heavy ion therapy facilities in China, objectively describes the technical features of...
Five sets of 240 MeV superconducting proton cyclotrons (SC240) have been successfully developed by Hefei CAS Ion Medical and Technical Devices Co., Ltd. (HFCIM) in collaboration with the Institute of Plasma Physics, Chinese Academy of Sciences. Two of these SC240 have been installed and are currently operational at dedicated proton therapy system in Hefei and Wuhan. The SC240 employs...
The construction and commissioning of the SPES facility is the flagship project of the INFN Legnaro National Laboratories. The goal is to build a state of the art accelerator facility to carry on research in the fields of Fundamental Physics and Interdisciplinary Physics. The core of the project is represented by a high-intensity cyclotron capable of delivering proton beams at 35-70 MeV with a...
Molecular imaging in nuclear medicine, based on radiopharmaceuticals, enables the diagnosis and evaluation of major diseases at the molecular level. The development and translation of radiopharmaceuticals driven by clinical needs represent the essence of nuclear medicine advancement. Existing radiopharmaceuticals, such as 18F-FDG, hailed as the "Molecule of the Century," play a critical role...
Peking University has built a fully integrated ecosystem for radiopharmaceutical research that spans radionuclide production, drug discovery, and clinical translation, catalyzing innovation at the interface of nuclear science and precision medicine. At its core is the Radiopharmaceutical Research Center (Cyclotron Platform), anchored by the CIAE-developed CYCIAE-14 cyclotron (14.6-MeV...
Several alpha-emitting radioisotopes, Ac-225, Ra-223, and Th-227, can be produced from natural thorium targets, primarily through nuclear reactions induced by a high-energy proton irradiation. These isotopes are of interest for targeted alpha therapy, a cancer treatment approach that utilizes the high energy of alpha particles to destroy cancer cells selectively. Ac-225 radioisotope decays...
